Last reviewed · How we verify
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.
Details
| Lead sponsor | AIM Vaccine Co., Ltd. |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 54 |
| Start date | 2022-09-16 |
| Completion | 2024-03 |
Conditions
- SARS-CoV-2
Interventions
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
- Placebo
Primary outcomes
- Incidence of solicited adverse events — Within 28 days after each dose/full dose
- Incidence of unsolicited adverse events — Within 28 days after each dose/full dose
- Incidence of adverse events associated with the study vaccine — Within 28 days after each dose/full dose
Countries
China